QURE

Business Context and Reporting Period

uniQure N.V. (QURE) is a gene therapy company focused on developing single treatments for rare and devastating diseases. This summary covers the unaudited quarterly period ended March 31, 2025. The company operates as a single segment, managing a pipeline including AMT-130 (Huntington's disease), AMT-260 (epilepsy), AMT-191 (Fabry disease), and AMT-162 (ALS). In January and February 2025, the company completed a follow-on public offering, raising approximately $80.7 million in net proceeds.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $6.9 million (81%) primarily due to the cessation of contract manufacturing and collaboration revenues following the divestiture of commercial manufacturing activities (Lexington Transaction) in July 2024. License revenue from HEMGENIX royalties increased slightly to $1.6 million.
• Improved Net Loss: Net loss narrowed by $22.0 million compared to Q1 2024. This improvement was driven by a $14.9 million reduction in operating expenses and a significant $8.3 million net foreign currency gain in Q1 2025 (vs. a $1.1 million loss in Q1 2024).
• One-Time Income: Other income increased by $6.9 million, largely due to a one-time $6.0 million gain from the sale of critical reagents to Genezen.
• Financing Activity: The company raised $80.7 million in net proceeds from a follow-on equity offering in Q1 2025, compared to no financing proceeds in Q1 2024.
• Debt Repayment: While the principal balance of the Hercules debt facility remained at $50.0 million, interest expense on this facility decreased by $1.9 million due to the repayment of $50.0 million in July 2024 and lower market rates.

Guidance, Outlook, and Risks

• Liquidity Runway: Management believes current cash and investment securities ($409.0 million) will fund operations through the second half of 2027.
• Regulatory Milestones:
  • AMT-130 (Huntington's): Received FDA Breakthrough Therapy designation in April 2025. The company has aligned with the FDA on an Accelerated Approval pathway and is preparing for a Biologics License Application (BLA) submission.
  • AMT-260 (Epilepsy): First patient dosed in November 2024; FDA approved protocol amendments in February 2025.
  • AMT-191 (Fabry): Independent Data Monitoring Committee (IDMC) recommended proceeding to the second cohort in February 2025.
  • AMT-162 (ALS): Enrollment in the second cohort completed; third cohort expected to initiate in Q3 2025.
• Key Risks:
  • Capital Needs: The company expects to incur significant losses and will require additional funding to advance clinical programs and support the commercial launch of AMT-130.
  • Manufacturing Dependence: Following the Lexington Transaction, the company relies on Genezen for manufacturing HEMGENIX and clinical supplies, introducing third-party performance risks.
  • Regulatory Uncertainty: Success depends on the FDA accepting data from Phase I/II studies for accelerated approval of AMT-130, which utilizes non-traditional study designs.
  • Debt Covenants: The company must maintain minimum cash balances and comply with covenants under its Hercules debt facility and Royalty Financing Agreement.

Investor Verification Checklist

• Cash Runway Validation: Verify if the projected burn rate aligns with the "second half of 2027" liquidity estimate, considering potential delays in BLA submission.
• AMT-130 Regulatory Pathway: Monitor upcoming FDA interactions regarding the pivotal statistical analysis plan and CMC requirements for the BLA.
• Genezen Manufacturing Performance: Assess Genezen's ability to meet supply obligations for HEMGENIX and clinical materials for the pipeline.
• Royalty Financing Liability: Review the effective interest rate assumptions (12.0% - 13.5%) and projected cash flows for the royalty financing agreement with HemB SPV.
• Equity Dilution: Evaluate the impact of the recent $80.7 million equity raise on shareholder dilution and future capital raising requirements.